A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6MEnded quarter with approximately $50M in cash, cash equivalents and restricted cashPlanned pivotal study for AR101 in Vascular Ehlers-Danlos Syndrome (VEDS) to begin in 1H22;...
ENGLEWOOD, CO / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on...
Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be addedENGLEWOOD, CO / September 9, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical...
ENGLEWOOD, CO / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer will...
ENGLEWOOD, CO / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that data from a laboratory study evaluating the ultraviolet A light...
Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 PatientsENGLEWOOD, CO / June 28, 2021 / Aytu BioPharma, Inc....
ENGLEWOOD, CO / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer, will present...
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) to development...
ENGLEWOOD, CO / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that in vitro data related to the ultraviolet (UV) A light used in the...
ENGLEWOOD, CO / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May...